Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H9N5O3 |
Molecular Weight | 271.2316 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+]1=CC(C=NNC(=O)CC#N)=[N+]([O-])C2=C1C=CC=C2
InChI
InChIKey=MBCZYLSVSCJJJQ-AUWJEWJLSA-N
InChI=1S/C12H9N5O3/c13-6-5-12(18)15-14-7-9-8-16(19)10-3-1-2-4-11(10)17(9)20/h1-4,7-8H,5H2,(H,15,18)/b14-7-
Ciadox is Quinoxaline 1,4-dioxide derivative with antimicrobial and promoting activities. Cyadox supplied as premix in the final feed in Eastern Europe and may be used in pigs up to four months of age. Some evidence demonstrated that the mechanism of Ciadox for improving pig growth performance was correlated with several metabolic hormones and growth factors. Cyadox also did not show any adverse effects in carcinogenicity tests with rats and long-term toxicity tests with mice and rats. Cyadox subchronic oral toxicity evaluation shows mild toxicity in non-rodents animals. Metabolic transformation of Ciadox leads to three major metabolites, including 1,4-bisdesoxycyadox, 4-desoxycyadox, and quinoxaline-2-carboxylic acid. Ciadox and metabolites shows virtually no toxic effects in the acute and subchronic oral toxicity study and no mutagenic, carcinogenic activivt.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26408151
pigs: 20 mg/kg of body weight for five consecutive days.
dogs: 100, 450 and 2500 mg/kg of cyadox, for 13 weeks.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C52588
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m3941
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
HX312O5UGN
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | |||
|
4857
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | |||
|
100000081898
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | |||
|
65884-46-0
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | |||
|
265-963-3
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | |||
|
DTXSID501014550
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | |||
|
135565684
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | |||
|
C83622
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104068
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY | |||
|
SUB06222MIG
Created by
admin on Sat Dec 16 17:07:16 GMT 2023 , Edited by admin on Sat Dec 16 17:07:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY